| [1] | SIEGEL R,AISHADHAM D,JEMAL A,et al.Cancer statistics,2012[J].CA Cancer J Clin,2012,62(1):10. |
| [2] | SCHILLER JH,HARRINGTON D,BELANI CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,46(2):92. |
| [3] | MOK TS,WU YL,THONGPRASERT S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):947. |
| [4] | ZHOU C,WU YL,CHEN G,et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,CTONG-0802):a multicentre,open-label,randomised,phase 3 study[J].Lancet Oncol,2011,12(8):735. |
| [5] | LOZANO MD,ZULUETA JJ,CHEVESTE JI,et al.Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients:correlation with clinical outcomes[J].Oncologist,2011,16(6):877. |
| [6] | SIMONE G,MANGIA A,MALFETTONE A,et al.Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer[J].J Exp Clin Cancer Res,2010,29(1):125. |
| [7] | FENTON KN,RICHARDSON JD.Diagnosis and management of malignant pleural effusions[J].Am J Surg,1995,170(1):69. |
| [8] | GUO J,ZHOU SW,ZHANG L,et al.Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer[J].J Cancer Res Clin Oncol,2010,136(9):1341. |
| [9] | GOW CH,CHANG YL,HSU YC,et al.Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer[J].Ann Oncol,2009,20(4):696. |
| [10] | LU SS,XU X,GUO HQ,et al.Detection of EGFR and K-ras mutations in non-small cell lung cancer using cytological specimens[J].Zhonghua Zhong Liu Za Zhi,2013,35(8):585. |
| [11] | SEMPERE LF,KORC M.Shining the spotlight on shed KRAS in pancreatic cancer[J].Cancer Biol Ther,2008,7(3):361. |
| [12] | AVIEL-RONEN S,BLACKHALL FH,SHEPHERD FA,et al.K-ras mutations in non-small-cell lung carcinoma:a review[J].Clin Lung Cancer,2006,8(1):30. |
| [13] | SIDDIQUI AD,PIPERDI B.KRAS mutation in colon cancer:a marker of resistance to EGFR-I therapy[J].Ann Surg Oncol,2010,17(4):1168. |
| [14] | MITSUDOMI T,MORITA S,YATABE Y,et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal grmb wth factor receptor(WJTOG3405):an open label,randomised phase 3 trial[J].Lancet Oncol,2010,11(2):121. |